Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVID-19

Dear Editor,

The pandemic of coronavirus disease 2019 (COVID-19) has stressed and overloaded the existing medical capacity worldwide. From a more pragmatic perspective, the early detection of patients who may experience rapid clinical deterioration will enable prompt interventions and avert disease progression. T cell exhaustion, immunothrombotic dysregulation, as well as complement-associated microvascular injury are considered as the hallmarks of disease severity in COVID-19. It is generally accepted that the identification of useful surrogates, for example, IL-6, TNFα, MIP1α, LDH, ferritin, D-dimer, CK, etc., to represent as immune response to COVID-19 infection is crucial. Nevertheless, no individual parameter was so far predictive of immune-thrombotic dysregulation fueled by a maladaptive host inflammatory response in severe infection with SARS-CoV-2. We, therefore, consider to develop potential solutions for forecasting thrombotic complications prior to clinicopathological exacerbation.

By incorporating whole blood transcriptome profiling and multi-omics analysis, our study characterized immunological and hematological perturbations with respect to different categories of severity (i.e., healthy donors vs. mild or moderate vs. severe vs. critical illness). Functional diversity was found among those groups by unsupervised hierarchical clustering of differential expression profiles (Figure 1A, left). Circus plots revealed that the differentially expressed genes (DEGs) were enriched into the key processes, that is, neutrophil activation, platelet activation, blood coagulation, complement receptor-mediated signaling pathway, leukocyte activation, and cytokines production. In contrast, the downregulated DEGs were functionally linked with lymphocyte activation, as well as vascular inflammation mediator PTX3 and activators.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
FIGURE 1  Transcriptional profiling of whole blood and multi-omics characterization of peripheral immune response in COVID-19 patients with different severity. (A) The diversity of gene-expression profiles in patients with different severity shown in unsupervised hierarchical clustering (Left). A circus plot shows transcriptional regulatory pathways, as well as network profiles from Gene Ontology Biological Process (GO-BPs) enrichment results of those differentially expressed genes (DEGs) (Right). The up- and down-regulated GO-BPs were represented by red and blue colors. (B) Heatmap and line charts display the differentially regulations of gene-subsets for platelet,
neutrophil-derived lactoferrin, were significantly upregulated in severe compared to critical illness (Figure 1D). NETs were described as important mediators of coagulation. Neutrophil activations correlated well with NETosis \((R = 0.98, p < 0.0001)\), as well as blood D-dimer concentrations \((R = 0.78, p < 0.001)\), highlighting a prominent role of activated neutrophils or NETosis in the pathogenesis of COVID-19 coagulopathy (Figure 1E, right).

The unveiled transcriptional findings were validated in a multicenter cohort of 1219 eligible individuals (Figure S1).

![Image of diagrams and tables](image_url)

**Figure 2** Critical blood parameters as well as age associated with disease severity of COVID-19 patients. (A–E) Boxplots depicting lymphocyte, neutrophil, platelet, hemoglobin, and age with respect to disease severity. \(* p < 0.05, ** p < 0.01, *** p < 0.001.\) (F) Correlation matrix of lymphocyte, neutrophil, platelet, and hemoglobin in the peripheral blood, as well as age in COVID-19 patients. (G) Intuitive three-dimensional plot shows the interplay of lymphocyte, neutrophil, platelet counts, and hemoglobin level in 1219 COVID-19 patients. (H–J) The featured outcomes from routine blood tests and age were examined independently by ROC curves in discriminating disease severity of COVID-19 patients.
FIGURE 3  ROC curves depict classification accuracy of the machine learning models and the overview of the performance for machine learning-based three-dimensional severity classifications. (A–D) Construction, evaluation, and validation of LASSO-based algorithms for disease severity classification. (E) GLM model. (F) LDA model. (G) Three-dimensional classification plot shows the performance for machine learning-based three-dimensional severity classifications based on identified features.
FIGURE 4  Construction, evaluation, and validation of algorithm for prognosis and fatal risks prediction. (A) LASSO Cox-based nomogram in training cohort for predicting 15-, 30-, and 45-days survival. Red dots represent a patient with total risk score is -0.832, overall death probabilities are 0.190, 0.303, and 0.419 within 15, 30, and 45 days, respectively. This patient is triaged as low risk. (B–D) Calibration, DCA, and net reduction plot for the nomogram. (E–G) The training cohort. (H–J) Internal testing cohort. (K–M) External validation cohort. We used AUCs at 15-, 30-, and 45-days to assess prognostic accuracy, and calculated p values using the log-rank test.
A summary of patient characteristics is provided (Table S1). Peripheral lymphocyte, neutrophil, platelet counts, as well as hemoglobin and ages among different severity groups were shown (Figure 2A–E). Besides, the demographically predictive protection against advancement of severity in COVID-19 is female sex, particularly for critically ill and lethal events (Figure S2). Consistent with transcriptional findings, clinical laboratory outcomes evidenced that lymphopenia, neutrophilia, as well as thrombocytopenia owning to the overconsumption of platelets were notably characterized in the late stages of COVID-19. And those features were of mutual linkages and exhibited correlation to varying degrees (Figure 2F). A three-dimensional simulation further implicated the dynamic interplay of lymphocyte, neutrophil, platelet, and hemoglobin (Figure 2G), providing a solid basis for mathematical modeling. Nonetheless, an individual blood parameter had relatively poor predictive performance for stratifying patients with different severity (Figure 2H–J and Table S2).

To improve the discrimination accuracy, machine learning-based severity classification was performed. LASSO regression classifier was applied to train the model utilizing the featured blood-parameters (Figure 3A). The calibration curve demonstrated a good consistence between the predicted and observed values and favorable predictive performance confirmed by receiver operating characteristic (ROC) analysis (Figure 3B–D). The discriminative ability was also assessed for testing and validation cohorts (Figure S3A–H). In parallel, the generalized linear model (GLM) and linear discriminant analysis (LDA) were utilized for the construction and optimization of disease discrimination. Strong discriminative capacities were achieved for both GLM (Figure 3E) and LDA (Figure 3F)-based algorithms. Eventually, the overall cohort of 1219 patients was stratified into different degrees of severity with a robust hierarchical classification capacity (Figure 3G).

Machine learning-based prognosis prediction was also studied (Figure 4A). The calibration curve and the diagonal coincided in general, indicating relatively high prediction accuracy for 15-, 30-, and 45-days in-hospital mortality risks (Figure 4B). A superior prediction capacity was demonstrated by decision curve analysis (DCA) and the net reduction in interventions was maximized (Figure 4C, D). The derived survival risk score was associated with immunethrombotic dysregulation. Patients in the training cohort could be, therefore, divided into high- and low-risk groups with significantly stratified fatal risks (Figure 4E). Area under curves (AUCs) of 0.73 (95% CI, 0.65–0.81), 0.80 (95% CI, 0.73–0.87), and 0.81 (95% CI, 0.72–0.90) for 15-, 30-, and 45-days were determined, and distinct survival outcomes were observed (p < 0.0001) (Figure 4F, G). Consistently, highly predictive performance was also evaluated in both internal testing (Figure 4H–J) and external validation cohort (Figure 4K–M).

In conclusion, genome-wide whole blood profiling was performed to deciphering the peripheral immune and hematologic perturbations to COVID-19, revealed an interesting feature of uncontrolled neutrophil-complement-coagulation interplay associated with immunethrombosis in severe and critically ill patients. Via machine learning techniques as well as the inclusion of large-scale multicenter cohorts of 1219 patients, an optimized precision of prediction algorithm by integrating platelet, neutrophil, and lymphocyte counts and hemoglobin was established. Taken together, we developed and validated mechanistic-driven rather than purely data-driven algorithms to assess the specific risks of immunothrombotic dysregulation in COVID-19. In principle, it might be used as a potential surrogate of decision-making for the ICU patients with coagulation abnormalities, enabling more timely interventions, such as low molecular weight heparin-treatment, and/or anticytokine therapies. Of note, those patients in ICUs are largely incapable of communicating and with very limited access to standard imaging utilizing computed tomography (CT). This algorithm will assist in guiding clinical decision-making in more individualized managements and provide insights for longitudinal surveillance of severe and critically ill individuals.

**FUNDINGS**

This work was supported by the National Natural Science Foundation of China (NSFC) (No. 81703166), Science and Technology Program of Guangzhou (Nos. 202002030445 and 202002030086), Natural Science Foundation of Guangdong Province (No. 2019A1515011943), China Postdoctoral Science Foundation (Nos. 2020T130052ZX and 2019M662974), and Medical Scientific Research Foundation of Guangdong Province (Nos. A2020505, A2020499, B2021203, and B2021139). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**CONFLICTS OF INTEREST**

The authors declare no potential conflicts of interest.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (approval number: NFEC-2020-033) and the Ethics Committees from the collaborated centers.
**AUTHOR CONTRIBUTIONS**

CZ, ZZ, PZ, and LW conceived and designed the study. XZ, LMC, TA, HG, HD, QY, YJL, XXL, XC, BN, SW, XLZ, JL, MXZ, and HY assisted in acquisition, analysis, interpretation of the data. ZZ, LW, DG, and CJ developed and validated the algorithms. ZZ, LW, DG, XZ, and LMC did the statistical and transcriptome analysis under the supervision of CZ, LHC, LBC, MLL, MJZ, and PZ. CZ, ZZ, and LW wrote the manuscript. BJ, AA, PZ, and LZ revised critically the study for important intellectual content. All authors have read and approved the final study.

**AVAILABILITY OF DATA AND MATERIALS**

The transcriptome sequencing data was deposited at the Gene Expression Omnibus under the accession number GSE167930.

Zhaoming Zhou1,2, †
Xiang Zhou3, †
Liming Cheng4, †
Lei Wen5
Taixue An6
Heng Gao7
Hongrong Deng8
Qi Yan9
Xinlu Zhang10
Youjiang Li11
Yixing Liao12
Xin-zu Chen13,14
Bin Nie15
Jie Cheng16,17
Guanhua Deng18
Shengqiang Wang19
Juan Li20
Hanqi Yin21
Mengxian Zhang22
Linbo Cai23
Lei Zheng24
Minglun Li25
Bleddyn Jones26
Longhua Chen27
Amir Abdollahi28
Meijuan Zhou29
Ping-Kun Zhou30
Cheng Zhou1,2,3

1 Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Department of Radiation Medicine, School of Public Health, Southern Medical University, Guangzhou, China
3 Department of Anesthesiology, General Hospital of Central Theater Command of PLA, Wuhan, China
4 Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China
6 Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Department of Neurosurgery, Jiangyin Affiliated Hospital of Southeast University School of Medicine, Jiangyin, China
8 Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
9 Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 Department of Clinical Laboratory, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China
12 Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 Department of Gastrointestinal and Hernia Surgery, The Second People’s Hospital of Yibin - West China Yibin Hospital, Sichuan University, Yibin, China
14 Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China
15 Department of Laboratory Medicine, The Second People’s Hospital of Yibin - West China Yibin Hospital, Sichuan University, Yibin, China
16 Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
17 Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
18 Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
19 South China Institute of Biomedicine, Guangzhou, China
20 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
21 Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany
22 Gray Laboratory, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
23 Translational Radiation Oncology, German Cancer Research Center (DKFZ) and University Heidelberg School of Medicine, Heidelberg, Germany
Correspondence
Cheng Zhou, Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Email: czhou.rob@gmail.com

Ping-Kun Zhou, Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Email: zhoupk@bmi.ac.cn

†These authors contributed equally to this article.

ORCID
Zhaoming Zhou https://orcid.org/0000-0002-9788-0184
Cheng Zhou https://orcid.org/0000-0003-3017-4135

REFERENCES
1. Pan C, Chen L, Lu C, et al. Lung recruitability in COVID-19-associated acute respiratory distress syndrome: a single-center observational study. Am J Respir Crit Care Med. 2020;201(10):1294-1297.
2. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020;324(15):1565-1567.
3. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1-13.
4. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369(6508):eabc8511
5. Zheng H-Y, Zhang M, Yang C-X, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541-543.
6. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-108.
7. Lazzaroni MG, Piantoni S, Masneri S, et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2020;46:100745.
8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.
9. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-e47.
10. von Brihl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
11. Tian W, Zhang N, Jin R, et al. Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020;11(1):5859.
12. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.